Publication: Primaquine to prevent transmission of falciparum malaria
Issued Date
2013-01-01
Resource Type
ISSN
14744457
14733099
14733099
Other identifier(s)
2-s2.0-84872595849
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
The Lancet Infectious Diseases. Vol.13, No.2 (2013), 181
Suggested Citation
Nicholas J. White Primaquine to prevent transmission of falciparum malaria. The Lancet Infectious Diseases. Vol.13, No.2 (2013), 181. doi:10.1016/S1473-3099(12)70198-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32589
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Primaquine to prevent transmission of falciparum malaria
Author(s)
Other Contributor(s)
Abstract
Falciparum malaria is transmitted by anopheline mosquitoes that have fed on blood containing gametocytes of Plasmodium falciparum. In areas of low malaria transmission, where symptomatic infections contribute substantially to malaria transmission, the use of gametocytocidal drugs reduces the incidence of malaria. Artemisinin-based combination therapies provide high cure rates and substantially reduce gametocyte carriage. Artemisinin resistance in P falciparum lessens overall gametocytocidal activity, which provides a selective pressure to the spread of these resistant parasites. The 8-aminoquinoline compounds possess unique gametocytocidal properties and rapidly sterilise the mature transmissible stages of P falciparum. The addition of one dose of primaquine to artemisinin-based combination regimens could help to counter the spread of artemisinin resistance. Although primaquine is commonly recommended for falciparum and vivax malaria, concerns about drug-related haemolysis frequently prevent its administration. The limited available evidence on transmission-blocking effects of primaquine and its forerunner plasmoquine suggests that doses lower than currently recommended (0·50-0·75 mg base per kg), which would be safer, might still be very effective. © 2013 Elsevier Ltd.